Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Vonoprazan/amoxicillin

From Wikipedia, the free encyclopedia
Combination medication

Pharmaceutical compound
Vonoprazan/amoxicillin
Combination of
VonoprazanPotassium-competitive acid blocker
AmoxicillinBeta-lactam antibiotic
Clinical data
Trade namesVoquezna Dual Pak
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status

Vonoprazan/amoxicillin, sold under the brand nameVoquezna Dual Pak among others, is a co-packaged medication used for the treatment ofHelicobacter pylori (H. pylori) infection.[1] It containsvonoprazan (as the fumarate), apotassium-competitive acid blocker andamoxicillin, abeta-lactam antibiotic.[1] It is takenby mouth.[1]

The co-packaged medication was approved for medical use in the United States in May 2022.[1][2][3][4]

Medical uses

[edit]

Vonoprazan/amoxicillin isindicated for the treatment ofH. pylori infection in adults.[1][5]

Research

[edit]

The dual therapy of using vonoprazan with amoxicillin has been investigated for the treatment ofH. pylori infection[6] and also compared with thetriple therapy of using vonoprazan,amoxicillin, andclarithromycin for the eradication ofH. pylori infection.[7] Both treatments have been found to be effective.[6][7] As of 2024,[update] evidence indicates that vonoprazan/amoxicillin therapy has similar efficacy tobismuth-containing quadruple therapies in eliminatingH. pylori.[8]

References

[edit]
  1. ^abcdef"Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit".DailyMed. 21 June 2022.Archived from the original on 3 July 2022. Retrieved3 July 2022.
  2. ^ab"Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults" (Press release). Phathom Pharmaceuticals. 3 May 2022.Archived from the original on 10 May 2022. Retrieved9 May 2022 – via GlobeNewswire.
  3. ^"Voquezna Dual Pak (amoxicillin and vonoprazan) FDA Approval History".Drugs.com.Archived from the original on 16 May 2022. Retrieved16 May 2022.
  4. ^"FDA NDA approval"(PDF).U.S.Food and Drug Administration (FDA). Archived fromthe original(PDF) on 12 May 2022. Retrieved12 May 2022.
  5. ^"Voquezna Dual Pak (vonoprazan/amoxicillin) monograph".Medscape. 5 May 2022.Archived from the original on 11 May 2022. Retrieved11 May 2022.
  6. ^abSuzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, et al. (June 2020)."Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan".Gut.69 (6):1019–1026.doi:10.1136/gutjnl-2019-319954.PMC 7282559.PMID 31915235.
  7. ^abFuruta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, et al. (November 2020). "Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori".Digestion.101 (6):743–751.doi:10.1159/000502287.PMID 31434101.S2CID 201277349.
  8. ^Pai L, Patil S, Liu S, Wen F (2023)."A growing battlefield in the war against biofilm-induced antimicrobial resistance: insights from reviews on antibiotic resistance".Front Cell Infect Microbiol.13 1327069.doi:10.3389/fcimb.2023.1327069.PMC 10770264.PMID 38188636.
H2 antagonists ("-tidine")
Prostaglandins (E)/
analogues ("-prost-")
Proton-pump inhibitors
("-prazole")
Potassium-competitive
acid blockers ("-prazan")
Others
Combinations
Portal:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Vonoprazan/amoxicillin&oldid=1329510333"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp